Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06112379




Registration number
NCT06112379
Ethics application status
Date submitted
12/10/2023
Date registered
1/11/2023
Date last updated
15/10/2024

Titles & IDs
Public title
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Scientific title
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Secondary ID [1] 0 0
D926QC00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dato-DXd
Treatment: Drugs - Durvalumab
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Epirubicin
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Carboplatin
Treatment: Drugs - Capecitabine
Treatment: Drugs - Olaparib

Experimental: Dato-DXd plus durvalumab - Participants receive durvalumab every 3 weeks (Q3W) + Dato-DXd Q3W as neoadjuvant therapy prior to surgery; followed by 9 cycles of durvaluamb Q3W as adjuvant therapy post-surgery. Adjuvant chemotherapy may be given in combination with durvalumab only if participants have residual disease.

Olaparib may be given for participants with gBRCA-positive tumours and residual disease

Adjuvant chemotherapy may be one of these:

1. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) and carboplatin (weekly or Q3W) for 4 cycles (12 weeks);
2. Doxorubicin (Q3W) or epirubicin (Q3W) + cyclophosphamide (Q3W) for 4 cycles (12 weeks) followed by paclitaxel (weekly) for 4 cycles (12 weeks);
3. Carboplatin (weekly or Q3W) + paclitaxel (weekly) for 4 cycles (12 weeks);
4. Capecitabine (Q3W) for 8 cycles.

Active comparator: Pembrolizumab plus chemotherapy - Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Adjuvant capecitabine (Q3W) for 8 cycles may be given in combination with pembrolizumab only if participants have residual disease. Olaparib may be given for participants with gBRCA-positive tumours and residual disease.


Treatment: Drugs: Dato-DXd
Experimental drug IV infusion

Treatment: Drugs: Durvalumab
Experimental drug IV Infusion

Treatment: Drugs: Pembrolizumab
IV Infusion Active comparator

Treatment: Drugs: Doxorubicin
IV infusion Experimental/Active Comparator

Treatment: Drugs: Epirubicin
IV Infusion Experimental/Active Comparator

Treatment: Drugs: Cyclophosphamide
IV infusion Experimental/Active Comparator

Treatment: Drugs: Paclitaxel
IV infusion Experimental/Active Comparator

Treatment: Drugs: Carboplatin
IV infusion Experimental/Active Comparator

Treatment: Drugs: Capecitabine
Tablet Oral route of administration Experimental/Active Comparator

Treatment: Drugs: Olaparib
Tablet Oral route of administration Experimental/Active Comparator
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pathologic Complete Response (pCR) in the experimental vs control arms
Timepoint [1] 0 0
At the time of definitive surgery
Primary outcome [2] 0 0
Event-free survival (EFS) in the experimental vs control arms
Timepoint [2] 0 0
Date of randomization to date of the EFS event, up to 68 months after the first subject randomized
Secondary outcome [1] 0 0
Overall Survival (OS) in the experimental vs control arms
Timepoint [1] 0 0
Date of randomization to date of death due to any cause, up to 82 months after the first subject randomized
Secondary outcome [2] 0 0
Distant disease-free survival (DDFS) in the experimental vs control arms
Timepoint [2] 0 0
Date of randomization to date of the DDFS event, up to 68 months after the first subject randomized
Secondary outcome [3] 0 0
Participant-reported breast and arm symptoms in the experimental vs. control arms
Timepoint [3] 0 0
From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first.
Secondary outcome [4] 0 0
Participant-reported physical function in the experimental vs. control arms
Timepoint [4] 0 0
From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).
Secondary outcome [5] 0 0
Participant-reported fatigue in the experimental vs. control arms
Timepoint [5] 0 0
From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).
Secondary outcome [6] 0 0
Participant-reported Global health status/Quality of life (GHS/QoL)in the experimental vs. control arms
Timepoint [6] 0 0
From Cycle 1 Day 1 of neoadjuvant treatment until pre-surgery safety FU visit (for approximately 24 weeks) or EOT - whichever occurs first, and then from Cycle 1 Day 1 of adjuvant treatment until EOT (for approximately 27 weeks).
Secondary outcome [7] 0 0
Pharmacokinetics of Dato-DXd (in combination with durvalumab)
Timepoint [7] 0 0
Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit
Secondary outcome [8] 0 0
Pharmacokinetics of Dato-DXd (in combination with durvalumab)
Timepoint [8] 0 0
Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit
Secondary outcome [9] 0 0
Pharmacokinetics of Dato-DXd (in combination with durvalumab)
Timepoint [9] 0 0
Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit
Secondary outcome [10] 0 0
Immunogenicity of Dato-DXd (in combination with durvalumab)
Timepoint [10] 0 0
Day 1 of cycles 1,2,4,8 (Each cycle is 21 days) and at pre-surgery safety follow up visit
Secondary outcome [11] 0 0
Safety of Dato-DXd (in combination with durvalumab)
Timepoint [11] 0 0
Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely

Eligibility
Key inclusion criteria
* Participant must be = 18 years, at the time of signing the ICF.
* Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer
* ECOG PS of 0 or 1
* Provision of acceptable tumor sample
* Adequate bone marrow reserve and organ function
* Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before randomization and of low potential risk for recurrence.
* Evidence of distant disease.
* Clinically significant corneal disease.
* Has active or uncontrolled hepatitis B or C virus infection.
* Known HIV infection that is not well controlled.
* Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.
* Known to have active tuberculosis infection
* Resting ECG with clinically significant abnormal findings.
* Uncontrolled or significant cardiac disease.
* History of non-infectious ILD/pneumonitis
* Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer
* For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.
* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/08/2030
Actual
Sample size
Target
1728
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Darlinghurst
Recruitment hospital [2] 0 0
Research Site - East Melbourne
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - Herston
Recruitment hospital [5] 0 0
Research Site - Nedlands
Recruitment hospital [6] 0 0
Research Site - Waratah
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
6009 - Nedlands
Recruitment postcode(s) [6] 0 0
2298 - Waratah
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Iowa
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Louisiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
Nevada
Country [22] 0 0
United States of America
State/province [22] 0 0
New Jersey
Country [23] 0 0
United States of America
State/province [23] 0 0
New Mexico
Country [24] 0 0
United States of America
State/province [24] 0 0
New York
Country [25] 0 0
United States of America
State/province [25] 0 0
North Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
Ohio
Country [27] 0 0
United States of America
State/province [27] 0 0
Oregon
Country [28] 0 0
United States of America
State/province [28] 0 0
Pennsylvania
Country [29] 0 0
United States of America
State/province [29] 0 0
Rhode Island
Country [30] 0 0
United States of America
State/province [30] 0 0
Tennessee
Country [31] 0 0
United States of America
State/province [31] 0 0
Texas
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Austria
State/province [35] 0 0
Feldkirch
Country [36] 0 0
Austria
State/province [36] 0 0
Graz
Country [37] 0 0
Austria
State/province [37] 0 0
Innsbruck
Country [38] 0 0
Austria
State/province [38] 0 0
Linz
Country [39] 0 0
Austria
State/province [39] 0 0
Salzburg
Country [40] 0 0
Belgium
State/province [40] 0 0
Brasschaat
Country [41] 0 0
Belgium
State/province [41] 0 0
Charleroi
Country [42] 0 0
Belgium
State/province [42] 0 0
Gent
Country [43] 0 0
Belgium
State/province [43] 0 0
Leuven
Country [44] 0 0
Belgium
State/province [44] 0 0
Libramont-Chevigny
Country [45] 0 0
Belgium
State/province [45] 0 0
Wilrijk
Country [46] 0 0
Brazil
State/province [46] 0 0
Brasilia
Country [47] 0 0
Brazil
State/province [47] 0 0
Curitiba
Country [48] 0 0
Brazil
State/province [48] 0 0
Fortaleza
Country [49] 0 0
Brazil
State/province [49] 0 0
Londrina
Country [50] 0 0
Brazil
State/province [50] 0 0
Natal
Country [51] 0 0
Brazil
State/province [51] 0 0
Porto Alegre
Country [52] 0 0
Brazil
State/province [52] 0 0
Ribeirão Preto
Country [53] 0 0
Brazil
State/province [53] 0 0
Santo Andre
Country [54] 0 0
Brazil
State/province [54] 0 0
São Paulo
Country [55] 0 0
Brazil
State/province [55] 0 0
Taubaté
Country [56] 0 0
Brazil
State/province [56] 0 0
Vitória
Country [57] 0 0
Bulgaria
State/province [57] 0 0
Plovdiv
Country [58] 0 0
Bulgaria
State/province [58] 0 0
Shumen
Country [59] 0 0
Bulgaria
State/province [59] 0 0
Sofia
Country [60] 0 0
Bulgaria
State/province [60] 0 0
Vratza
Country [61] 0 0
Canada
State/province [61] 0 0
Alberta
Country [62] 0 0
Canada
State/province [62] 0 0
British Columbia
Country [63] 0 0
Canada
State/province [63] 0 0
Newfoundland and Labrador
Country [64] 0 0
Canada
State/province [64] 0 0
Ontario
Country [65] 0 0
Canada
State/province [65] 0 0
Quebec
Country [66] 0 0
Canada
State/province [66] 0 0
Saskatchewan
Country [67] 0 0
Canada
State/province [67] 0 0
Montreal
Country [68] 0 0
Canada
State/province [68] 0 0
Ottawa
Country [69] 0 0
China
State/province [69] 0 0
Beijing
Country [70] 0 0
China
State/province [70] 0 0
Bengbu
Country [71] 0 0
China
State/province [71] 0 0
Changchun
Country [72] 0 0
China
State/province [72] 0 0
Changsha
Country [73] 0 0
China
State/province [73] 0 0
Chengdu
Country [74] 0 0
China
State/province [74] 0 0
Chongqing
Country [75] 0 0
China
State/province [75] 0 0
Guangzhou
Country [76] 0 0
China
State/province [76] 0 0
Hangzhou
Country [77] 0 0
China
State/province [77] 0 0
Harbin
Country [78] 0 0
China
State/province [78] 0 0
Hefei
Country [79] 0 0
China
State/province [79] 0 0
Jinan
Country [80] 0 0
China
State/province [80] 0 0
Kunming
Country [81] 0 0
China
State/province [81] 0 0
Linhai
Country [82] 0 0
China
State/province [82] 0 0
Nanchang
Country [83] 0 0
China
State/province [83] 0 0
Nanjing
Country [84] 0 0
China
State/province [84] 0 0
Nanning
Country [85] 0 0
China
State/province [85] 0 0
Shanghai
Country [86] 0 0
China
State/province [86] 0 0
Shenyang
Country [87] 0 0
China
State/province [87] 0 0
Shijiazhuang
Country [88] 0 0
China
State/province [88] 0 0
Suining
Country [89] 0 0
China
State/province [89] 0 0
Suzhou
Country [90] 0 0
China
State/province [90] 0 0
Tianjin
Country [91] 0 0
China
State/province [91] 0 0
Urumqi
Country [92] 0 0
China
State/province [92] 0 0
Wuhan
Country [93] 0 0
China
State/province [93] 0 0
Xi'an
Country [94] 0 0
China
State/province [94] 0 0
Xintai
Country [95] 0 0
China
State/province [95] 0 0
Zhengzhou
Country [96] 0 0
France
State/province [96] 0 0
Avignon
Country [97] 0 0
France
State/province [97] 0 0
Bayonne
Country [98] 0 0
France
State/province [98] 0 0
Caen Cedex 5
Country [99] 0 0
France
State/province [99] 0 0
Clermont Ferrand
Country [100] 0 0
France
State/province [100] 0 0
Limoges
Country [101] 0 0
France
State/province [101] 0 0
Lyon
Country [102] 0 0
France
State/province [102] 0 0
Marseille
Country [103] 0 0
France
State/province [103] 0 0
Montpellier
Country [104] 0 0
France
State/province [104] 0 0
Nice
Country [105] 0 0
France
State/province [105] 0 0
Paris
Country [106] 0 0
France
State/province [106] 0 0
Reims Cedex
Country [107] 0 0
France
State/province [107] 0 0
Saint Herblain
Country [108] 0 0
France
State/province [108] 0 0
Toulouse
Country [109] 0 0
France
State/province [109] 0 0
Vandoeuvre les Nancy
Country [110] 0 0
France
State/province [110] 0 0
Villejuif Cedex
Country [111] 0 0
Germany
State/province [111] 0 0
Augsburg
Country [112] 0 0
Germany
State/province [112] 0 0
Berlin
Country [113] 0 0
Germany
State/province [113] 0 0
Dessau-Roßlau
Country [114] 0 0
Germany
State/province [114] 0 0
Dresden
Country [115] 0 0
Germany
State/province [115] 0 0
Erlangen
Country [116] 0 0
Germany
State/province [116] 0 0
Essen
Country [117] 0 0
Germany
State/province [117] 0 0
Esslingen am Neckar
Country [118] 0 0
Germany
State/province [118] 0 0
Frankfurt am Main
Country [119] 0 0
Germany
State/province [119] 0 0
Freiburg
Country [120] 0 0
Germany
State/province [120] 0 0
Hannover
Country [121] 0 0
Germany
State/province [121] 0 0
Heidelberg
Country [122] 0 0
Germany
State/province [122] 0 0
Kiel
Country [123] 0 0
Germany
State/province [123] 0 0
Mainz
Country [124] 0 0
Germany
State/province [124] 0 0
Mannheim
Country [125] 0 0
Germany
State/province [125] 0 0
München
Country [126] 0 0
Germany
State/province [126] 0 0
Münster
Country [127] 0 0
Germany
State/province [127] 0 0
Trier
Country [128] 0 0
Germany
State/province [128] 0 0
Ulm
Country [129] 0 0
Hong Kong
State/province [129] 0 0
Hong Kong
Country [130] 0 0
Hong Kong
State/province [130] 0 0
Kwai Chung
Country [131] 0 0
Hungary
State/province [131] 0 0
Budapest
Country [132] 0 0
Hungary
State/province [132] 0 0
Kecskemét
Country [133] 0 0
Hungary
State/province [133] 0 0
Miskolc
Country [134] 0 0
Hungary
State/province [134] 0 0
Nyíregyháza
Country [135] 0 0
Hungary
State/province [135] 0 0
Salgótarján
Country [136] 0 0
Hungary
State/province [136] 0 0
Szekszárd
Country [137] 0 0
India
State/province [137] 0 0
Bengaluru
Country [138] 0 0
India
State/province [138] 0 0
Dehradun
Country [139] 0 0
India
State/province [139] 0 0
Delhi
Country [140] 0 0
India
State/province [140] 0 0
Kolkata
Country [141] 0 0
India
State/province [141] 0 0
Marg Jaipur
Country [142] 0 0
India
State/province [142] 0 0
Nagpur
Country [143] 0 0
India
State/province [143] 0 0
Nashik
Country [144] 0 0
India
State/province [144] 0 0
Puducherry
Country [145] 0 0
India
State/province [145] 0 0
Thiruvananthapuram
Country [146] 0 0
India
State/province [146] 0 0
Vadodara
Country [147] 0 0
Italy
State/province [147] 0 0
Empoli
Country [148] 0 0
Italy
State/province [148] 0 0
Lucca
Country [149] 0 0
Italy
State/province [149] 0 0
Macerata
Country [150] 0 0
Italy
State/province [150] 0 0
Milano
Country [151] 0 0
Italy
State/province [151] 0 0
Modena
Country [152] 0 0
Italy
State/province [152] 0 0
Napoli
Country [153] 0 0
Italy
State/province [153] 0 0
Padova
Country [154] 0 0
Italy
State/province [154] 0 0
Roma
Country [155] 0 0
Italy
State/province [155] 0 0
Rozzano
Country [156] 0 0
Italy
State/province [156] 0 0
Torino
Country [157] 0 0
Italy
State/province [157] 0 0
Tricase
Country [158] 0 0
Italy
State/province [158] 0 0
Udine
Country [159] 0 0
Japan
State/province [159] 0 0
Akashi-shi
Country [160] 0 0
Japan
State/province [160] 0 0
Akita-shi
Country [161] 0 0
Japan
State/province [161] 0 0
Bunkyo-ku
Country [162] 0 0
Japan
State/province [162] 0 0
Chiba-shi
Country [163] 0 0
Japan
State/province [163] 0 0
Chuo-ku
Country [164] 0 0
Japan
State/province [164] 0 0
Fukuoka-shi
Country [165] 0 0
Japan
State/province [165] 0 0
Fukushima-shi
Country [166] 0 0
Japan
State/province [166] 0 0
Gifu-shi
Country [167] 0 0
Japan
State/province [167] 0 0
Hidaka-shi
Country [168] 0 0
Japan
State/province [168] 0 0
Hirakata-shi
Country [169] 0 0
Japan
State/province [169] 0 0
Hiroshima-shi
Country [170] 0 0
Japan
State/province [170] 0 0
Isehara-shi
Country [171] 0 0
Japan
State/province [171] 0 0
Kashiwa
Country [172] 0 0
Japan
State/province [172] 0 0
Koto-ku
Country [173] 0 0
Japan
State/province [173] 0 0
Kumamoto-shi
Country [174] 0 0
Japan
State/province [174] 0 0
Kurume-shi
Country [175] 0 0
Japan
State/province [175] 0 0
Kyoto-shi
Country [176] 0 0
Japan
State/province [176] 0 0
Matsuyama-shi
Country [177] 0 0
Japan
State/province [177] 0 0
Nagoya-shi
Country [178] 0 0
Japan
State/province [178] 0 0
Niigata-shi
Country [179] 0 0
Japan
State/province [179] 0 0
Okayama
Country [180] 0 0
Japan
State/province [180] 0 0
Osaka-shi
Country [181] 0 0
Japan
State/province [181] 0 0
Sapporo-shi
Country [182] 0 0
Japan
State/province [182] 0 0
Sendai-shi
Country [183] 0 0
Japan
State/province [183] 0 0
Shinagawa-ku
Country [184] 0 0
Japan
State/province [184] 0 0
Shinjuku-ku
Country [185] 0 0
Japan
State/province [185] 0 0
Sunto-gun
Country [186] 0 0
Japan
State/province [186] 0 0
Tokyo
Country [187] 0 0
Japan
State/province [187] 0 0
Tsu-shi
Country [188] 0 0
Japan
State/province [188] 0 0
Yokohama-shi
Country [189] 0 0
Korea, Republic of
State/province [189] 0 0
Daegu
Country [190] 0 0
Korea, Republic of
State/province [190] 0 0
Goyang-si
Country [191] 0 0
Korea, Republic of
State/province [191] 0 0
Seongnam
Country [192] 0 0
Korea, Republic of
State/province [192] 0 0
Seoul
Country [193] 0 0
Malaysia
State/province [193] 0 0
George Town
Country [194] 0 0
Malaysia
State/province [194] 0 0
Kuala Lumpur
Country [195] 0 0
Malaysia
State/province [195] 0 0
Kuching
Country [196] 0 0
Malaysia
State/province [196] 0 0
Selangor
Country [197] 0 0
Poland
State/province [197] 0 0
Bialystok
Country [198] 0 0
Poland
State/province [198] 0 0
Bydgoszcz
Country [199] 0 0
Poland
State/province [199] 0 0
Gdansk
Country [200] 0 0
Poland
State/province [200] 0 0
Gdynia
Country [201] 0 0
Poland
State/province [201] 0 0
Tomaszów Mazowiecki
Country [202] 0 0
Poland
State/province [202] 0 0
Warszawa
Country [203] 0 0
Poland
State/province [203] 0 0
Wroclaw
Country [204] 0 0
Poland
State/province [204] 0 0
Lódz
Country [205] 0 0
Singapore
State/province [205] 0 0
Singapore
Country [206] 0 0
Spain
State/province [206] 0 0
Barcelona
Country [207] 0 0
Spain
State/province [207] 0 0
Granada
Country [208] 0 0
Spain
State/province [208] 0 0
Hospitalet deLlobregat
Country [209] 0 0
Spain
State/province [209] 0 0
Madrid
Country [210] 0 0
Spain
State/province [210] 0 0
Santiago de Compostela
Country [211] 0 0
Spain
State/province [211] 0 0
Sevilla
Country [212] 0 0
Spain
State/province [212] 0 0
Zaragoza
Country [213] 0 0
Switzerland
State/province [213] 0 0
Baden
Country [214] 0 0
Switzerland
State/province [214] 0 0
Basel
Country [215] 0 0
Switzerland
State/province [215] 0 0
Bern
Country [216] 0 0
Switzerland
State/province [216] 0 0
Frauenfeld
Country [217] 0 0
Switzerland
State/province [217] 0 0
Rennaz
Country [218] 0 0
Taiwan
State/province [218] 0 0
Changhua
Country [219] 0 0
Taiwan
State/province [219] 0 0
Kaohsiung
Country [220] 0 0
Taiwan
State/province [220] 0 0
Taichung
Country [221] 0 0
Taiwan
State/province [221] 0 0
Tainan
Country [222] 0 0
Taiwan
State/province [222] 0 0
Taipei
Country [223] 0 0
Taiwan
State/province [223] 0 0
Taoyuan
Country [224] 0 0
Thailand
State/province [224] 0 0
Bangkok
Country [225] 0 0
Thailand
State/province [225] 0 0
Dusit
Country [226] 0 0
Thailand
State/province [226] 0 0
Muang
Country [227] 0 0
Thailand
State/province [227] 0 0
Songkhla
Country [228] 0 0
Turkey
State/province [228] 0 0
Adapazari
Country [229] 0 0
Turkey
State/province [229] 0 0
Ankara
Country [230] 0 0
Turkey
State/province [230] 0 0
Istanbul
Country [231] 0 0
Turkey
State/province [231] 0 0
Kayseri
Country [232] 0 0
Turkey
State/province [232] 0 0
Samsun
Country [233] 0 0
United Kingdom
State/province [233] 0 0
Birmingham
Country [234] 0 0
United Kingdom
State/province [234] 0 0
Cardiff
Country [235] 0 0
United Kingdom
State/province [235] 0 0
Edinburgh
Country [236] 0 0
United Kingdom
State/province [236] 0 0
Guildford
Country [237] 0 0
United Kingdom
State/province [237] 0 0
Lancaster
Country [238] 0 0
United Kingdom
State/province [238] 0 0
London
Country [239] 0 0
United Kingdom
State/province [239] 0 0
Northampton
Country [240] 0 0
United Kingdom
State/province [240] 0 0
Oxford
Country [241] 0 0
United Kingdom
State/province [241] 0 0
Taunton
Country [242] 0 0
Vietnam
State/province [242] 0 0
Hanoi
Country [243] 0 0
Vietnam
State/province [243] 0 0
Ho Chi Minh city
Country [244] 0 0
Vietnam
State/province [244] 0 0
Vinh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Daiichi Sankyo
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Trial website
https://clinicaltrials.gov/study/NCT06112379
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06112379